TICKERNERD
Menu
MASSMASSHealthcare · Medical Devices

MASS Stock Forecast: 908 Devices, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$11
+3.19% on the day

The 5 Wall Street analysts covering 908 Devices, Inc. hold a median 12-month price target of $13 — +21.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 84 of 100 as at 22 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$441.4M
Ticker Nerd rank
84 / 100
Median analyst target
$13
Analysts covering
5
Total return, dividends reinvested
1W
+6.7%
1M
+45.3%
YTD
+103.4%
1Y
+77.4%
From 52W high
0.0%
From 52W low
+109.8%
$5
$11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MASS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores 908 Devices, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
84 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
87
Accruals
86
Momentum
82
Quality
65
Value
59
Revisions
57
Size
56
Issuance
45
Volatility
39

Growth (87): Sales and profits are climbing, and climbing faster than before.

Volatility (39): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MASS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MASS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$4$6$8$10$12$14Oct 25Jan 26Apr 26Jul 26MASSHigh $14Median $13Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $12Median $13High $14

The green dot is the last close — the median target sits +21.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
12 Aug 2026Roth CapitalMaintainsBuy$11 → $13
12 Aug 2026StifelMaintainsBuy$10 → $12
29 July 2026Roth CapitalInitiatesBuy$11
29 July 2026Roth CapitalInitiatesBuy—
5 Aug 2025Leerink PartnersUpgradeOutperform—
5 Aug 2025Leerink PartnersUpgradeOutperform$12
15 Jan 2025Stephens & Co.ReiteratesOverweight—
13 Nov 2024Leerink PartnersDowngradeMarket Perform—
13 Nov 2024StifelMaintainsBuy—
17 Oct 2024Leerink PartnersMaintainsOutperform—
13 May 2024Stephens & Co.ReiteratesOverweight—
25 Sept 2023Stephens & Co.ReiteratesOverweight—
7 Feb 2023Stephens & Co.InitiatesOverweight—
6 Jan 2023SVB LeerinkMaintainsOutperform—
15 Nov 2022SVB LeerinkMaintainsOutperform—
8 Mar 2022SVB LeerinkMaintainsOutperform—
14 May 2021SVB LeerinkMaintainsOutperform—
12 Jan 2021Cowen & Co.InitiatesOutperform—
12 Jan 2021StifelInitiatesBuy—
12 Jan 2021SVB LeerinkInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MASS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

MASS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

908 Devices, Inc. (MASS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
19.8×

Cheaper than 39% of US stocks

Price / sales
7.3×

Cheaper than 18% of US stocks

Price / book
3.0×

Cheaper than 35% of US stocks

EV / EBITDA
−20.9×

Cheaper than 89% of US stocks

Growth & margins
Revenue growth (YoY)
23.3%

Higher than 73% of US stocks

Earnings growth (YoY)
13.6%

Higher than 52% of US stocks

Gross margin
51.4%

Higher than 64% of US stocks

Operating margin
−39.6%

Higher than 18% of US stocks

Net margin
−57.0%

Higher than 9% of US stocks

Returns & dividend
Return on equity
−25.0%

Higher than 29% of US stocks

Return on assets
−6.8%

Higher than 29% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

MASS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
MASS908 Devices, Inc.$441.4M
84
SGHTSight Sciences, Inc.$446.1M
86
CLPTClearpoint Neuro, Inc.$457.8M
20
SIShoulder Innovations, Inc.$459.3M
18
PACBPacific Biosciences of California, Inc.$407.7M
43
NPCENeuroPace, Inc.$472.3M
90
OFIXOrthofix Medical, Inc.$396.4M
81

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own 908 Devices, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MASS news & analysis

TG Therapeutics Conference: 908 Devices Bets on Handheld Drug, Chemical Detection

MarketBeat · 18 Aug 2026neutral

908 Devices outlined its strategy to focus exclusively on handheld chemical and drug detection technologies for public safety and defense markets, following the divestiture of its life-sciences business line about 15 months ago, as presented at the TG Therapeutics conference.

Why it matters — MASS watchers would care because the company is positioning itself around a concentrated handheld detection portfolio for public safety and defense after its life-sciences divestiture.

908 Devices Eyes Growth in Handheld Drug and Chemical Detection Market

MarketBeat · 15 Aug 2026neutral

908 Devices is sharpening its focus on handheld chemical and drug detection systems for public safety, defense and law enforcement, executives said during a Canaccord Genuity discussion following the divestiture of its bioprocessing and biopharma business line.

Why it matters — The divestiture signals a strategic pivot that redefines 908 Devices' core business, so the company's go-forward revenue and growth prospects now hinge on its handheld detection segment.

908 Devices Q2: Another Solid Report

Seeking Alpha · 13 Aug 2026positive

908 Devices reported another Q2 revenue beat, with revenue up 23% year-over-year to $16.07 million and product revenue up nearly 35.5% as the installed base expanded 23%. Management raised 2026 revenue guidance to $68–$70 million while operating and net losses narrowed.

Why it matters — A MASS watcher would care because the report shows continued revenue growth, an expanding installed base, raised full-year guidance, and narrowing losses at the company.

908 Devices: Mission Critical Devices Drive Growth

Seeking Alpha · 12 Aug 2026positive

908 Devices reported a 2Q26 earnings beat and strong revenue growth driven by demand for chemical detection devices from law enforcement and defense amid volatile geopolitical conditions. The company raised its FY26 revenue guidance to $68–70M, supported by recurring revenue from NIRLab and product upgrades such as VipIR.

Why it matters — MASS watchers would care because the company raised its revenue guidance and is benefiting from recurring revenue streams and product upgrades amid strong demand for chemical detection devices.

908 Devices to Present at the 17th Annual Midwest IDEAS Investor Conference

Business Wire · 12 Aug 2026neutral

908 Devices announced that CEO Kevin J. Knopp and CFO Joe Griffith will present and host investor meetings at the 17th Annual Midwest IDEAS Conference on Wednesday, August 26, 2026. The company's presentation is scheduled to begin at 9:55 a.m. CT / 10:55 a.m. ET.

Why it matters — This conference appearance gives investors an opportunity to hear directly from 908 Devices' senior leadership about the company's business.

FAQ

Frequently asked questions about MASS stock

What is the MASS stock price forecast for 2026-2027?

The 5 Wall Street analysts covering 908 Devices, Inc. have a median 12-month price target of $13, with estimates ranging from $12 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MASS stock a buy right now?

Of the 5 analysts covering 908 Devices, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks 908 Devices, Inc. 84 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MASS?

As at 22 Aug 2026, 908 Devices, Inc. ranks 84 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (87 of 100).

Will MASS stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +21.7% from the last close, and Ticker Nerd's factor model ranks 908 Devices, Inc. 84 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MASS stock forecast for 2030?

No analyst covering 908 Devices, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MASS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $14 over the next 12 months.

How has MASS stock performed over the past year?

908 Devices, Inc. returned +77.4% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does 908 Devices, Inc. do?

908 Devices Inc. is a cutting-edge biotechnology firm specializing in the design and development of innovative chemical analysis devices.

What is the latest news on MASS?

The most recent item we track (MarketBeat, 18 Aug 2026): "TG Therapeutics Conference: 908 Devices Bets on Handheld Drug, Chemical Detection". 908 Devices outlined its strategy to focus exclusively on handheld chemical and drug detection technologies for public safety and defense markets, following the divestiture of its life-sciences business line about 15 months ago, as presented at the TG Therapeutics conference.

Company

About 908 Devices, Inc.

908 Devices Inc. is a cutting-edge biotechnology firm specializing in the design and development of innovative chemical analysis devices. The primary mission of 908 Devices Inc. is to deliver straightforward, portable analytical tools that enhance chemical and biochemical analysis processes across various sectors. Their suite of devices includes handheld, desktop, and small-scale instruments that facilitate real-time, point-of-need analytics, empowering end-users in industries such as life sciences, pharmaceuticals, and public safety. These devices are crucial in applications like drug development, environmental monitoring, and forensic investigation, offering precision and ease of access. With a commitment to advancing technology and miniaturizing complex instrumentation, 908 Devices Inc. significantly contributes to increasing efficiency and accuracy in analytical methodologies, thereby supporting vital decision-making processes in diverse fields. By merging engineering excellence with scientific insight, this company plays an essential role in pushing the boundaries of traditional laboratory-based analysis, bringing sophisticated solutions to everyday use cases in the market.

CEO Dr. Kevin J. Knopp Ph.D. · 172 employees · United States · https://908devices.com